Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;63(9):1271-1282.
doi: 10.1007/s40262-024-01410-2. Epub 2024 Aug 22.

Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections

Pier Giorgio Cojutti  1   2 , Sara Tedeschi  3   4 , Eleonora Zamparini  4 , Pierluigi Viale  3   4 , Federico Pea  3   5
Affiliations

Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections

Pier Giorgio Cojutti et al. Clin Pharmacokinet. 2024 Sep.

Abstract

Background and objective: Dalbavancin is increasingly used for the long-term treatment of chronic osteoarticular infections. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis for assessing the relationship between dalbavancin exposure and C-reactive protein (C-RP) over time was conducted.

Methods: Non-linear mixed-effect modeling was fitted to dalbavancin and C-RP concentrations. Monte Carlo simulations assessed the weekly percentage of C-RP reduction associated with different dosing regimens, starting from baseline to < 1 mg/dL.

Results: A total of 45 patients were retrospectively included in the analysis. The PK of dalbavancin was described by a two-compartment model, and the PD of C-RP was described by an indirect turnover maximum inhibition model. The total dalbavancin concentration model estimate producing 50% of maximum C-RP production inhibition (IC50) was 0.70 mg/L. Monte Carlo simulations showed that in patients with staphylococcal osteoarticular infections targeting total dalbavancin concentrations at > 14.5 mg/L at any time point may achieve C-RP production inhibition over time in > 95% of patients. Based on this, the findings showed that a cumulative dose of 3000 mg administered in the first 3 weeks may lead to a > 90% C-RP decrease versus baseline in approximately 5-6 weeks. In patients needing treatment prolongation, an additional 1500 mg dose after this period may maintain C-RP concentrations < 1 mg/dL for other 3 weeks.

Conclusions: A decrease in C-RP is related to dalbavancin exposure in osteoarticular infections. Targeting dalbavancin plasma concentrations above the efficacy threshold may be associated with effective treatment.

PubMed Disclaimer

Conflict of interest statement

Pier Giorgio Cojutti received fees from Angelini, Shionogi, Pfizer, and MSD outside of the submitted work. Federico Pea reports personal fees from Angelini, Basilea Pharmaceutica, Gilead, Hikma, MSD, Pfizer, Sanofi-Aventis, Shionogi, Thermo Fisher, and Accelerate Diagnostics, outside the submitted work; has participated in speakers’ bureaus for Accelerate Diagnostics, Angelini, Basilea Pharmaceutica, Gilead, Hikma, MSD, Pfizer, Sanofi-Aventis, Shionogi, and Thermo Fisher; and has been a consultant for Angelini, Basilea Pharmaceutica, Gilead, MSD, Pfizer, and Shionogi, outside the submitted work. Pierluigi Viale has served as a consultant for bioMérieux, Gilead, Merck Sharp and Dohme, Nabriva, Nordic Pharma, Pfizer, Thermo-Fisher, and Venatorx, and has received payment for serving on the speakers’ bureaus for Correvio, Gilead, Merck Sharp, and Dohme, Nordic Pharma, and Pfizer, outside the submitted work. Sara Tedeschi and Eleonora Zamparini report no potential conflicts of interest that may be relevant to the contents of this study.

Figures

Fig. 1
Fig. 1
Prediction-corrected visual predictive check for the population (a) pharmacokinetic and (b) pharmacodynamic models. By default, three prediction intervals are displayed, one for each of the following percentiles of observed data: 10th, 50th and 90th percentiles. Prediction intervals are estimated across all simulated data and are displayed as colored areas (pink for the 50th percentile, blue for the 10th and 90th percentiles). Each prediction interval is computed with a level of 90%. The continuous blue lines indicate the 10th, 50th and 90th percentiles for observed data. C-RP C-reactive protein
Fig. 2
Fig. 2
Relationship between dalbavancin concentration and extent of inhibition effect for C-RP production after 10,000 Monte Carlo simulations using the population values and between-subject variability from the PK/PD model. The solid and dashed lines represent the median and 90% prediction interval of the extent of the inhibition effect, respectively. The gray vertical dotted lines represent the IC50 (0.70 mg/L) and the 95% percentile of the IC50 (14.5 mg/L). C-RP C-reactive protein, IC50 half maximal inhibitory concentration, PD pharmacodynamic, PK pharmacokinetic
Fig. 3
Fig. 3
Percentage reduction of estimated median C-RP over time after administering a total dalbavancin dose of 3000 mg in the first 3 weeks in relation to different schedule regimens and classes of renal function. Horizonal dotted lines identify a 90% probability of C-RP reduction. In the eGFR 60–89 mL/min/1.73 m2 class, the 1.5 g D1 + 1.5 g D8 group is overlaid to that of the 1.5 g D1 + 0.5 g D8 + 0.5 g D15 + 0.5 g D22 group. C-RP C-reactive protein, D day, eGFR estimated glomerular filtration rate
Fig. 4
Fig. 4
Percentage reduction of estimated median C-RP over time after an initial total dalbavancin dose of 3000 mg in the first 3 weeks in relation to different schedule regimens followed by an additional 1500 mg dose at D43 in relation to different classes of renal function. Horizonal dotted lines identify a 90% probability of C-RP reduction. C-RP C-reactive protein, D day, eGFR estimated glomerular filtration rate
See this image and copyright information in PMC

References

    1. Smith JR, Roberts KD, Rybak MJ. Dalbavancin: A novel lipoglycopeptide antibiotic with extended activity against gram-positive infections. Infect Dis Ther. 2015;4(3):245–58. - DOI - PMC - PubMed
    1. Molina KC, Miller MA, Mueller SW, Van Matre ET, Krsak M, Kiser TH. Clinical pharmacokinetics and pharmacodynamics of dalbavancin. Clin Pharmacokinet. 2022;61(3):363–74. - DOI - PubMed
    1. Oliva A, Stefani S, Venditti M, Di Domenico EG. Biofilm-related infections in gram-positive bacteria and the potential role of the long-acting agent dalbavancin. Front Microbiol. 2021;12: 749685. - DOI - PMC - PubMed
    1. Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849–55. - DOI - PMC - PubMed
    1. Cojutti PG, Tedeschi S, Gatti M, Zamparini E, Meschiari M, Siega PD, et al. Population pharmacokinetic and pharmacodynamic analysis of dalbavancin for long-term treatment of subacute and/or chronic infectious diseases: the major role of therapeutic drug monitoring. Antibiotics. 2022;11(8):996. - DOI - PMC - PubMed

MeSH terms